Concorde Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $557K | Sell |
2,563
-200
| -7% | -$44.4K | 0.27% | 82 |
|
|
2025
Q4 | $631K | Sell |
2,763
-186
| -6% | -$42.4K | 0.25% | 89 |
|
|
2025
Q3 | $702K | Buy |
+2,949
| New | +$601K | 0.29% | 74 |
|
|
2025
Q1 | $521K | Sell |
2,896
-13
| -0.4% | -$2.53K | 0.28% | 60 |
|
|
2024
Q4 | $517K | Sell |
2,909
-194
| -6% | -$35.7K | 0.27% | 60 |
|
|
2024
Q3 | $613K | Sell |
3,103
-48
| -2% | -$8.96K | 0.35% | 49 |
|
|
2024
Q2 | $540K | Buy |
3,151
+81
| +3% | +$13.4K | 0.33% | 54 |
|
|
2024
Q1 | $559K | Buy |
3,070
+214
| +7% | +$36.9K | 0.38% | 47 |
|
|
2023
Q4 | $443K | Hold |
2,856
| – | – | 0.3% | 61 |
|
|
2023
Q3 | $426K | Sell |
2,856
-20,503
| -88% | -$3.01M | 0.38% | 55 |
|
|
2023
Q2 | $3.13M | Sell |
23,359
-6,317
| -21% | -$926K | 2.89% | 7 |
|
|
2023
Q1 | $4.69M | Buy |
29,676
+27,677
| +1,385% | +$4.23M | 5.56% | 4 |
|
|
2022
Q4 | $289K | Buy |
1,999
+42
| +2% | +$6.44K | 0.26% | 97 |
|
|
2022
Q3 | $238K | Buy |
+1,957
| New | +$281K | 0.27% | 112 |
|
|
2022
Q2 | – | Sell |
-2,132
| Closed | -$317K | – | 108 |
|
|
2022
Q1 | $317K | Buy |
2,132
+578
| +37% | +$84K | 0.21% | 106 |
|
|
2021
Q4 | $214K | Sell |
1,554
-1,104
| -42% | -$130K | 0.13% | 152 |
|
|
2021
Q3 | $295K | Buy |
2,658
+639
| +32% | +$73K | 0.17% | 149 |
|
|
2021
Q2 | $230K | Sell |
2,019
-8,131
| -80% | -$916K | 0.13% | 164 |
|
|
2021
Q1 | $1.11M | Buy |
+10,150
| New | +$1.09M | 0.64% | 53 |
|
|
2020
Q3 | – | Sell |
-2,183
| Closed | -$209K | – | 179 |
|
|
2020
Q2 | $209K | Buy |
+2,183
| New | +$192K | 0.17% | 117 |
|
|
2020
Q1 | – | Sell |
-2,848
| Closed | -$250K | – | 102 |
|
|
2019
Q4 | $250K | Sell |
2,848
-182
| -6% | -$15.1K | 0.17% | 114 |
|
|
2019
Q3 | $239K | Sell |
3,030
-721
| -19% | -$49.4K | 0.18% | 122 |
|
|
2019
Q2 | $293K | Buy |
3,751
+54
| +1% | +$4.24K | 0.17% | 162 |
|
|
2019
Q1 | $296K | Sell |
3,697
-193
| -5% | -$15.8K | 0.19% | 146 |
|
|
2018
Q4 | $315K | Buy |
3,890
+333
| +9% | +$29.3K | 0.27% | 115 |
|
|
2018
Q3 | $288K | Buy |
3,557
+795
| +29% | +$75.4K | 0.28% | 95 |
|
|
2018
Q2 | $203K | Sell |
2,762
-159
| -5% | -$15.5K | 0.23% | 117 |
|
|
2018
Q1 | $212K | Sell |
2,921
-170
| -5% | -$18.7K | 0.26% | 107 |
|
|
2017
Q4 | $223K | Buy |
3,091
+5
| +0.2% | +$471 | 0.28% | 97 |
|
|
2017
Q3 | $244K | Sell |
3,086
-1,054
| -25% | -$80.2K | 0.21% | 120 |
|
|
2017
Q2 | $301K | Buy |
+4,140
| New | +$278K | 0.41% | 87 |
|
|
2017
Q1 | – | Sell |
-4,072
| Closed | -$255K | – | 113 |
|
|
2016
Q4 | $255K | Sell |
4,072
-10,065
| -71% | -$614K | 0.46% | 82 |
|
|
2016
Q3 | $892K | Buy |
+14,137
| New | +$915K | 1.12% | 25 |
|
Other funds holding ABBV
VCM
VPM
Concorde Asset Management's ABBV Position: Q1 2026 in Review
Concorde Asset Management reduced its AbbVie (ABBV) stake by 7.2% in Q1 2026, selling an estimated $44.4K and leaving 2,563 shares worth $557K. The position accounts for 0.27% of the portfolio, ranked #82.
Concorde Asset Management first reported a position in ABBV in Q3 2016 and has held it in 33 quarters since. The position peaked at $4.69M in Q1 2023. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Concorde Asset Management held 2,563 shares of AbbVie worth $557K as of Q1 2026.
- Concorde Asset Management sold 200 AbbVie shares in Q1 2026, an estimated $44.4K.
- AbbVie made up 0.27% of Concorde Asset Management's portfolio in Q1 2026, its #82 holding.
- Concorde Asset Management first reported a position in AbbVie in Q3 2016 and has held it in 33 quarters since.
- Concorde Asset Management's AbbVie position peaked at $4.69M in Q1 2023.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Concorde Asset Management's 13F filing for Q1 2026, filed 1 Jun 2026.